Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24710342 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1NPC1MAPK1HTT | |
| SCHEMBL2007841 | 0.84 | CES2 (0.69) | SMN1; SMN2ALDH1A1NPC1MAPK1KMT2A | |
| SCHEMBL30771287 | 0.83 | CYP2C9 (0.46) | SMN1; SMN2ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL906436 | 0.83 | CES2 (0.64) | ALDH1A1HTTCES2CES1 | |
| SCHEMBL3258075 | 0.82 | MEN1 (0.64) | SMN1; SMN2ALDH1A1NPC1MAPK1HTT | |
| SCHEMBL31465704 | 0.81 | CYP3A4 (0.61) | SMN1; SMN2ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL6278770 | 0.80 | KDM4E (0.58) | SMN1; SMN2ALDH1A1NPC1HTTPKM | |
| SCHEMBL31135473 | 0.79 | GAA (0.52) | SMN1; SMN2ALDH1A1NPC1HTTKMT2A | |
| SCHEMBL6450300 | 0.79 | CES2 (0.58) | ALDH1A1NPC1HTTHPGDGAA | |
| SCHEMBL25508540 | 0.79 | CES2 (0.64) | SMN1; SMN2ALDH1A1NPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| CN-109627239-B | Inhibitors of fibroblast growth factor receptors | 缆图药品公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-111793068-A | Heteroaryl compounds and uses thereof | 西建卡尔有限责任公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-1953147-A1 | HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF | Japan Tobacco, Inc. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885ALDH1A1 684/4885NPC1 48/4885 |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | SMN1; SMN2 4164/4885ALDH1A1 2530/4885NPC1 3772/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | SMN1; SMN2 3076/4885ALDH1A1 3220/4885NPC1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.